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Background: Several studies have suggested that Helicobacter pylori (H. pylori)
infection is a risk factor for colorectal cancer (CRC), while others have not confirmed this
hypothesis. This work aimed to assess the relation of CRCwithH. pylori seropositivity and
with seropositivity to 16 H. pylori proteins, in the MultiCase-Control study, MCC-Spain.
Methods: MCC-Spain is a multicase-control study carried out in Spain from 2008
to 2013. In total, 2,140 histologically-confirmed incident CRC cases and 4,098
population-based controls were recruited. Controls were frequency-matched by sex,
age, and province. Epidemiological data were collected through a questionnaire
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fulfilled by face-to-face interviews and a self-administered food-frequency questionnaire.
Seroreactivities against 16 H. pylori proteins were determined in 1,488 cases and 2,495
controls usingH. pylorimultiplex serology.H. pylori seropositivity was defined as positivity
to ≥4 proteins. Multivariable logistic regression mixed models were used to estimate
odds ratios (OR) and 95% confidence intervals (CI).
Results: H. pylori seropositivity was not associated with increased CRC risk (OR
= 0.91; 95% CI: 0.71–1.16). Among H. pylori seropositive subjects, seropositivity to
Cagδ showed a lower CRC risk, and risk decreased with increasing number of proteins
seropositive. Seropositivity to the most recognized virulence factors, CagA and VacA,
was not associated with a higher CRC risk. No statistically significant heterogeneity
was identified among tumor sites, although inverse relations were stronger for left colon
cancer. An interaction with age and sex was found:H. pylori seropositivity was associated
with a lower CRC risk in men younger than 65 and with a higher risk in older women.
Conclusions: Our results suggest that neither H. pylori seropositivity, nor seropositivity
to the virulence factor CagA are associated with a higher CRC risk. A possible effect
modification by age and sex was identified.
Keywords: Helicobacter pylori, multiplex serology, colorectal neoplasm, chronic infection, bacterial infections,
non-infectious diseases
INTRODUCTION
Helicobacter pylori (H. pylori) is the Helicobacter species that
predominantly infects humans. According to the usual site of
colonization, Helicobacter species can be divided into gastric
and enteric or enterohepatic Helicobacter types (International
Agency for Research on Cancer, 2012). Though most literature
on the implication of H. pylori in the etiopathogenesis of cancer
refers to gastric cancer [adenocarcinoma and low-grade B-cell
mucosa-associated lymphoid tissue (MALT) gastric lymphoma],
there are also studies investigating its role in cancer of other
organs of the digestive system, including esophagus, colon and
rectum, pancreas, and biliary tract (Siddheshwar et al., 2001;
Trikudanathan et al., 2011; Sonnenberg and Genta, 2013; Xiao
et al., 2013; Murphy et al., 2014; Wang et al., 2014; Chen et al.,
2015), and even of extra-digestive organs, such as lung or larynx
(Rezaii et al., 2008; Mounika, 2013).
Regarding a possible association between H. pylori infection
and colorectal cancer (CRC) risk, there are no consistent results
in the scientific literature. Several meta-analyses (Zumkeller et al.,
2006; Zhao et al., 2008; Hong et al., 2012; Chen et al., 2013;
Rokkas et al., 2013; Wu et al., 2013; Guo and Li, 2014; Liu and
Zheng, 2016) have obtained combined odds ratios (OR) over the
unity (range from 1.08 to 1.63), suggesting an increased CRC
risk associated with H. pylori infection. However, heterogeneity
among studies and insufficient control for confounding factors in
most of them entail a high degree of uncertainty, which precludes
from deriving solid conclusions. Biological plausibility has been
investigated and several mechanisms have been proposed to
explain an increased risk of CRC due to H. pylori infection. The
most established involve the increase of gastrin secretion, the
modification of gut microbiota and the chronic inflammation
status (Chang and Parsonnet, 2010; Tatishchev et al., 2012;
Papastergiou, 2016). However, two recent publications, one
reporting results from a nested case-control study including
a Caucasian population from the US (Blase et al., 2016) and
another from a cohort study in Germany (Chen et al., 2016),
not included in the above mentioned meta-analyses, did not find
a statistically significant association between H. pylori infection
and CRC.
The pathogenicity of different H. pylori strains colonizing
the gastric mucosa has been involved in modulating the risk of
gastric adenocarcinoma. Whether such an effect also exists for
CRC has been studied to a lesser extent, but could be one of the
factors contributing to heterogeneity among the studies’ results.
H. pylori multiplex serology is a recently developed technique
able to quantify seroreactivity against severalH. pylori proteins in
a wide set of serum samples in a single assay. It therefore allows
obtaining a detailed characterization of the serological response
against H. pylori, as a surrogate marker of differences in bacterial
protein expression patterns, in large population samples.
The aims of this study are to evaluate the association between
H. pylori seropositivity as well as seropositivity against 16
individual H. pylori proteins and CRC risk. CRC cases and
controls of the MCC-Spain study were examined, controlling for
the main potential confounding factors and exploring differences
among cancer sites, age groups, and sex.
MATERIALS AND METHODS
Study Population
We used data from the participants in the MCC-Spain multicase-
control project, a large multicenter study with population-based
controls. This study aimed to investigate environmental and
genetic factors involved in the etiology of various forms of cancer.
Following a standardized protocol, patients with a new diagnosis
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of gastric, colorectal, breast, or prostate cancer, and chronic
lymphocytic leukemia cases, aged 20–85 years, were invited to
participate in 23 hospitals from 12 Spanish geographical regions
(provinces). All cases had lived in the catchment area of each
hospital for at least 6 months prior to diagnosis. Each province
recruited at least two different cancer types. In parallel, a single
group of population-based controls was randomly selected from
the general population living in the catchment areas of the
collaborating hospitals, frequency-matched for age and sex to the
whole set of cases included in each province. Recruitment started
in September 2008 and lasted until December 2013, though the
period of recruitment differed by hospital. Of the 23 hospitals,
18 from 11 Spanish provinces recruited CRC cases: Asturias,
Barcelona, Cantabria, Gipuzkoa, Granada, Huelva, León,Madrid,
Murcia, Navarra, and Valencia. The Ethical Review Board of each
participating center approved the study protocol. All participants
provided written informed consent for their enrolment in the
study.More details regarding the design of the study are provided
elsewhere (Castaño-Vinyals et al., 2015).
Data Collection
Experienced interviewers conducted structured interviews to
cases and controls, to collect information on socio-demographic
factors, life-styles, weight and height at various periods of life,
occupational history, medical history, and family history of
cancer. Dietary habits were obtained through a food-frequency
questionnaire provided to each participant at the interview
for self-fulfillment and returned by mail. Following the study
protocol, all cases and controls were asked to donate a blood
sample. Specimens were refrigerated locally until being processed
and aliquoted (in <48 h). Then, they were stored at –80◦C until
they were sent to the laboratory.
In total, 2,140 histopathologically confirmed CRC cases and
3,950 controls were included. The analysis presented here is
based on 1,488 (70%) CRC cases and 2,495 (63%) controls. Main
reasons for not being included in the analysis were not having
donated a blood sample and sample not having been processed
by multiplex serology (Figure 1).
Laboratory Assays
Seroreactivities against 16 H. pylori proteins were determined
using H. pylori multiplex serology (Supplementary Table 1).
Multiplex serology is a glutathione S-transferase (GST)
capture immunosorbent assay combined with fluorescent-bead
technology, as described elsewhere (Waterboer et al., 2005). This
technique simultaneously quantifies antibodies directed against
an array of antigens. In brief, bacterially expressed recombinant
GST-H. pylori fusion proteins were used as antigens. The
fusion proteins were loaded and affinity-purified directly on
individual sets of spectrally distinct glutathione-casein-coupled
fluorescence-labeled polystyrene beads (SeroMap, Luminex,
Austin, TX). Bead sorts, each carrying a different antigen,
were mixed and incubated with human sera at 1:100 dilutions.
Antibodies bound to the beads via the bacterial antigens were
stained by biotinylated anti-human-IgA, IgM, IgG (Dianova,
Hamburg, Germany), and streptavidin-R-phycoerythrin. Beads
were examined in a Luminex 200 analyzer that quantifies
the antibody bound to bacterial antigen via the median R-
phycoerythrin fluorescence intensity of at least 100 beads of the
same internal color. Net (bead and GST background subtracted)
median reporter fluorescence intensity (MFI)-values were
calculated and negative values were set to+1.
For H. pylori proteins, serostatus cut-offs were calculated
(mean MFI + 3 SD, excluding positive outliers) in 17 H. pylori
negative sera previously classified for H. pylori status run within
FIGURE 1 | Flow of colorectal cancer cases and controls through the MCC-Spain study stages. CRC, Colorectal cancer; MS, Multiplex serology.
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the same experiment. According to these cut-offs (Supplementary
Table 1), each participant was classified as seropositive or
seronegative to each protein. Following previously published
criteria, H. pylori seropositivity was defined as positivity for at
least four of the 15H. pylori proteins (excluding HomB, a protein
recently added toH. pylorimultiplex serology). Subjects fulfilling
this criterion were considered infected (Michel et al., 2009).
Statistical Analysis
Cases and controls characteristics were summarized by
frequencies and percentages for categorical variables, and by
means and standard deviations for continuous variables. To
test for possible differences among cases and controls, and
among infected and non-infected controls in the distribution
of potential confounding factors, univariate (chi-squared or
Mann-Whitney U-test for categorical and continuous variables,
respectively) and multivariable (logistic regression) analyses
were done.
Multivariable logistic regression mixed models were used to
quantify the association betweenH. pylori seropositivity andCRC
risk, estimating ORs and their 95% confidence intervals (CI).
First a basic model (model 1) was built, that was adjusted for
gender, age (as a continuous variable), and education. Secondly,
a model including potential confounders such as smoking status,
bodymass index (BMI), and family history of CRCwas developed
(model 2). Lastly a fully adjusted model was done (model 3), that
was additionally adjusted by ethanol intake at age 30–40 (g/day)
and dietary factors: total energy intake (calories/day), vegetables
intake (g/day), and red and processed meat intake (g/day). In all
models province was included as a random-effect term.
Among H. pylori positive cases and controls, the association
between serostatus against each of the 16 proteins and CRC risk
was then investigated. Multivariable logistic regression mixed
models were used, adjusting by gender, age, education level,
smoking status, and CRC family history. As a sensitivity analysis,
models additionally adjusted by BMI, ethanol intake at age 30–40
and dietary factors were constructed. Province was included as a
random-effect term.
For those proteins whose serostatus resulted independently
associated with CRC risk, dose-response relation was assessed
by analyzing the association between seroreactivity and CRC
risk. Seroreactivity was categorized in tertiles, based on the
distribution of the MFI for each protein in infected controls
seropositive against that protein.
A possible differential effect by tumor site was analyzed. For
this purpose, multinomial logistic regression mixed models were
fitted. Heterogeneity of the effects was assessed using a Wald-
test comparing the coefficients obtained for the different CRC
sites. Tumors located in cecum, ascending colon, hepatic flexure
or transverse colon were grouped as right colon cancer, those
located in the splenic flexure, descending colon or sigmoid, as
left colon and tumors classified as rectosigmoideal were grouped
with rectum cancer cases.
To assess the association of seropositivity against each protein
independent of serostatus of other proteins, a multivariable
logistic regression mixed analysis was carried out simultaneously
including all the proteins associated with colorectal, colon, or
rectum cancer with a p < 0.10 in the individual analyses also
adjusting by gender, age, education, smoking status, and CRC
family history.
Effect modification by age, sex, and education was explored
by comparing models with and without the interaction term and
assessed through the likelihood-ratio test. Age was dichotomized
using as cut-off value the median of the age in controls.
Stratified analyses were performed where interaction was
present.
The raw data analyzed for the current study are not publicly
available due to confidentiality related restrictions, but they
would be available from the last author or from one of the co-
principal investigators on reasonable request [Dr. N. Aragonés
(naragones@isciii.es)/Dr. M. Pollán (mpollan@isciii.es)].
RESULTS
Cases of CRC were predominantly men (64%), had a mean age
of 67 years (SD: 11) and a low education (72% primary school or
lower). Controls were, on average, 3 years younger, with lower
history of CRC among their first-degree relatives and had a
higher education level (Table 1). With respect to differences in
dietary habits, controls had higher intake of vegetables, nuts and
smoked foods, lower intake of red and processed meat, and lower
overall energy intake. Clinico-pathological characteristics of cases
are summarized in Supplementary Table 2. Tumor was located
in the colon in 910 cases [402 (27%) right colon, 507 (34%)
left colon, and 1 not specified], and in the rectum in 556 cases
(37%). For 22 cases (1.5%) colon or rectum location could not be
classified. Most tumors were adenocarcinomas (97%).
Overall, H. pylori seropositivity was 88% (95% CI: 86–89)
in controls and 90% (95% CI: 88–91) in CRC cases, with no
differences by tumor anatomic site. Distribution of potential
confounding factors by H. pylori serostatus in controls is
presented in Supplementary Table 3. Among factors associated
with the case/control status in the univariable analysis in our
sample, sex, age, education, BMI, alcohol consumption, and
intakes of vegetables and nuts appeared associated also with
the exposure to H. pylori infection in controls. However, after
mutually adjusting by factors with a p < 0.10 in the univariable
analysis, only sex and intake of vegetables were associated with
H. pylori serostatus using a p-value limit of 0.05 (data not shown).
In Table 2 seroprevalence for each H. pylori protein among
infected controls and cases can be seen. The highest prevalences
were detected for GroEL, NapA, HP231, and Omp, and the
lowest for HpaA, HomB, and Cad. Infected to non-infected
seropositivity ratio were highest for HcpC (20 in controls and 32
in cases) and lowest for HomB (two both, in controls and cases).
As shown in Table 3, in the multivariable analysis H. pylori
seropositivity was not statistically significantly associated with
a higher CRC risk, neither in the basal model, nor in models
adjusted by different sets of covariates. An inverse relation
between the number of proteins with seroreactivity above
the corresponding cut-off level and CRC risk emerged when
adjusting by BMI and/or diet and alcohol consumption variables.
CRC risk was 5% lower for each additional seropositive protein.
By tumor site, H. pylori infection tended to be associated with a
Frontiers in Microbiology | www.frontiersin.org 4 May 2017 | Volume 8 | Article 888
Fernández de Larrea-Baz et al. H. pylori Seroreactivities and Colorectal Cancer
TABLE 1 | Characteristics of colorectal cancer cases and controls.
Variable Controls (N = 2,495) Casesa
All (N = 1,488) Colon (N = 910) Rectum (N = 556)
N (%) N (%) p-values N (%) p-values N (%) p-values
Sex <0.001 <0.001 <0.001
Male 1,275 (51) 945 (64) 552 (61) 376 (68)
Female 1,220 (49) 543 (36) 358 (39) 180 (32)
Age (years)b 63.6 [11.7] 66.7 [10.6] <0.001 67.3 [10.6] <0.001 65.8 [10.6] <0.001
Race 0.521 0.510 0.192
White/Caucasian 2,451 (98) 1,465 (98) 891 (98) 552 (99)
Other 42 (2) 23 (2) 19 (2) 4 (1)
Missing 2 (0) 0 (0) 0 (0) 0 (0)
Education <0.001 <0.001 <0.001
No/incomplete primary school 482 (19) 471 (32) 291 (32) 176 (32)
Primary school 891 (36) 589 (40) 356 (39) 224 (40)
Secondary school 685 (27) 284 (19) 169 (19) 109 (20)
University degree 437 (18) 144 (10) 94 (10) 47 (8)
Smoking status 0.013 0.039 0.023
Never smoker 1,099 (44) 612 (41) 398 (44) 208 (37)
Former smoker 854 (34) 577 (39) 345 (38) 223 (40)
Current smoker 533 (21) 289 (19) 161 (18) 122 (22)
Missing 9 (0) 10 (1) 6 (1) 3 (1)
Past ethanol intakec <0.001 0.003 0.029
No drinker 611 (24) 377 (25) 235 (26) 136 (24)
Light 455 (18) 205 (14) 127 (14) 77 (14)
Upper recommended limit 505 (20) 280 (19) 162 (18) 113 (20)
Abundant 440 (18) 285 (19) 166 (18) 114 (21)
Heavy/Very heavy 205 (8) 166 (11) 101 (11) 62 (11)
Missing 279 (11) 175 (12) 119 (13) 54 (10)
BMI (kg/m2) <0.001 <0.001 0.008
<25 788 (32) 331 (22) 183 (20) 142 (26)
25–29.9 930 (37) 540 (36) 324 (36) 211 (38)
≥30 437 (18) 304 (20) 195 (21) 103 (19)
Missing 340 (14) 313 (21) 208 (23) 100 (18)
CRC family history <0.001 <0.001 <0.001
No CRC family history 2,212 (89) 1,162 (78) 719 (79) 425 (76)
Only 2nd degree relatives 65 (3) 58 (4) 37 (4) 20 (4)
≥1 first degree relatives 207 (8) 255 (17) 145 (16) 107 (19)
Missing 11 (0) 13 (1) 9 (1) 4 (1)
Mean [SD] Mean [SD] p-values Mean [SD] p-values Mean [SD] p-values
Diet related variables
Total energy (cal/d) 1,901.3 [557.4] 2,019.3
[631.3]
<0.001 1,989.1
[611.1]
<0.001 2,061.0
[657.6]
<0.001
Fruits (g/d) 357.0 [217.2] 349.8 [199.0] 0.548 360.0 [200.5] 0.42 337.3 [197.2] 0.071
Vegetables (g/d) 193.8 [122.9] 175.9 [106.3] <0.001 181.5 [107.8] 0.009 169.1 [104.1] <0.001
Red/processed meat (g/d) 61.9 [38.1] 74.9 [47.8] <0.001 72.3 [45.8] <0.001 78.6 [50.2] <0.001
Smoked cold meat/fish (g/d) 3.3 [8.4] 2.9 [8.3] <0.001 2.7 [7.8] <0.001 3.1 [8.9] 0.003
Nuts (g/d) 7.9 [13.3] 7.1 [12.2] 0.008 7.1 [12.8] 0.003 7.0 [11.4] 0.357
Dairy (g/d) 364.9 [186.1] 366.6 [190.4] 0.995 376.1 [189.9] 0.234 352.8 [191.6] 0.147
Fiber (g/d) 22.9 [9.1] 22.5 [8.2] 0.301 22.5 [8.1] 0.417 22.5 [8.4] 0.606
(Continued)
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TABLE 1 | Continued
Variable Controls (N = 2,495) Casesa
All (N = 1,488) Colon (N = 910) Rectum (N = 556)
Mean [SD] Mean [SD] p-values Mean [SD] p-values Mean [SD] p-values
Calcium (mg/d) 924.8 [306.2] 934.1 [326.6] 0.651 942.4 [326.5] 0.301 924.0 [329.1] 0.702
D vitamin (mcg/d) 2.7 [1.5] 2.8 [1.6] 0.951 2.7 [1.6] 0.717 2.8 [1.7] 0.716
METS 2–12 years before diagnosis 154.8 [263.1] 141.8 [260.6] <0.001 129.2 [237.3] <0.001 163.3 [295.9] 0.035
BMI, Body mass index; CRC, Colorectal cancer; METS, Metabolic Equivalent Units.
aFor 22 cases site information was not available.
bValues represent mean and standard deviations.
cAlcohol intake categories (based on g/d of ethanol intake): Light: ≤6; Upper recommended limit: women >6 to ≤12 and men >6 to ≤24; Abundant: women: >12 to ≤24 and men
>24 to ≤60; Heavy/Very heavy: women >24 and men >60. For continuous variables, analysis was done over participants with complete information: 2,216 controls and 1,313 cases
for diet variables; 2,494 controls and all cases for physical activity (METS). In the multivariable logistic regression analysis including variables with a p < 0.10 in any of the comparisons
in the table, age, education, family history of colorectal cancer, total energy intake, and intakes of vegetables, nuts, red and processed meat, and smoked food were associated with
CRC at a p < 0.05.
TABLE 2 | Seroprevalence for H. pylori proteins among infecteda controls
and colorectal cancer cases.
Controls Casesb
(N = 2,186) All Colon Rectum
(N = 1,335) (N = 814) (N = 500)
N (%) N (%) N (%) N (%)
GroEL+ 1,962 (90) 1,234 (92) 757 (93) 459 (92)
NapA+ 1,806 (83) 1,138 (85) 692 (85) 429 (86)
HP231+ 1,758 (80) 1,055 (79) 637 (78) 401 (80)
Omp+ 1,613 (74) 990 (74) 586 (72) 387 (77)
HyuA+ 1,440 (66) 906 (68) 553 (68) 338 (68)
VacA+ 1,346 (62) 790 (59) 471 (58) 307 (61)
Catalase+ 1,308 (60) 760 (57) 464 (57) 287 (57)
UreA+ 1,198 (55) 710 (53) 433 (53) 267 (53)
HP305+ 1,169 (53) 658 (49) 391 (48) 256 (51)
CagA+ 1,168 (53) 743 (56) 465 (57) 269 (54)
CagM+ 1,100 (50) 677 (51) 412 (51) 257 (51)
Cagδ+ 1,065 (49) 590 (44) 339 (42) 242 (48)
HcpC+ 989 (45) 563 (42) 334 (41) 221 (44)
HpaA+ 804 (37) 435 (33) 270 (33) 163 (33)
HomB+ 779 (36) 456 (34) 279 (34) 173 (35)
Cad+ 711 (33) 410 (31) 251 (31) 154 (31)
Number of proteins+
4–7 716 (33) 457 (34) 280 (34) 171 (34)
7–12 1,043 (48) 665 (50) 412 (51) 241 (48)
≥12 427 (20) 213 (16) 122 (15) 88 (18)
Number of proteins+c 8.9 [2.8] 8.7 [2.6] 8.7 [2.6] 8.9 [2.6]
aPositive for 4 or more H. pylori proteins.
bFor 22 cases site information was not available.
cMean [SD] of the number of proteins against which antibody reactivities were above the
corresponding cut-off value.
lower risk of left colon cancer, although result of the statistical
test for heterogeneity was not significant.
Among H. pylori infected subjects, only seropositivity against
GroEL and NapA showed a positive association with CRC
risk, although CIs were wide (Figure 2). On the contrary,
seropositivity to HP305, HpaA, and Cagδwas related to a 15–21%
lower risk of CRC compared to seronegativity against each of
these proteins. An inverse relation was observed between the
number of seropositivities and CRC risk, showing a 3% lower
risk for each seropositive protein. No remarkable differences were
apparent in the direction or the magnitude of these associations
depending on tumor site. Only the estimated effect of Cagδ
showed heterogeneity among sites according to the statistical
test. Seropositivity for this protein was associated with a 26
and 32% lower risk of right and left colon cancer, respectively,
while only a non-statistically significant 6% lower risk was
observed for rectum cancer. Additionally, for HP305 and HpaA
the magnitude of the association was stronger (lower ORs)
and statistically significant for left colon cancer, although the
direction of the estimated ORs were the same (under the unity)
for all sites and statistical test for heterogeneity did not reach
the significance level (Figure 2). Additional adjustment of the
models by BMI, ethanol consumption and diet factors resulted in
a stronger inverse association for some of the antigens’ serostatus
(Supplementary Figure 1).
Adjusting simultaneously by serostatus against all those
proteins individually associated with risk (GroEL, HP305, HpaA,
Cagδ, and Catalase), only Cagδ remained inversely associated at
a statistically significant level with CRC (OR = 0.81; 95% CI:
0.70–0.94). By tumor site, Cagδ seropositivity remained inversely
associated with right and left colon cancers (OR = 0.76; 95%
CI: 0.60–0.96 and OR = 0.71; 95% CI: 0.57–0.88, respectively)
and HP305 only with left colon cancer (OR = 0.75; 95% CI:
0.60–0.94). Seropositivity to GroEL appeared related to a higher
CRC (OR = 1.33; 95% CI: 1.01–1.74) and left colon cancer risk
(OR = 1.62; 95% CI: 1.06–2.48). For rectal cancer, ORs showed
the same directions than for the other sites, but with wider
CIs, and none of them was statistically significant. Heterogeneity
among tumor sites was nearly statistically significant only for the
effect of Cagδ (p= 0.055). A dose-response pattern was observed
for these associations. Higher seroreactivity against GroEL was
associated with increasing CRC risk (8% higher for each tertile
with respect to seronegativity; p = 0.049), and for Cagδ and
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TABLE 3 | Association between colorectal cancer and H. pylori infection.
Colorectala Right colonb Left colonb Rectumb
OR 95% CI p-values OR 95% CI p-values OR 95% CI p-values OR 95% CI p-values p-het
MODEL 1
H. pylori+ 1.03 0.83–1.29 0.775 1.33 0.90–1.96 0.150 0.84 0.62–1.13 0.244 1.05 0.77–1.44 0.761 0.118
Number of proteins+
<4 1.00 1.00 1.00 1.00
4–7 1.08 0.85–1.38 0.522 1.35 0.89–2.04 0.164 0.89 0.64–1.24 0.492 1.12 0.79–1.57 0.533 0.231
7–12 1.09 0.86–1.37 0.483 1.45 0.97–2.18 0.069 0.88 0.64–1.22 0.453 1.06 0.76–1.48 0.715 0.114
≥12 0.81 0.62–1.07 0.135 0.99 0.62–1.59 0.981 0.62 0.42–0.92 0.016 0.90 0.61–1.32 0.592 0.178
Trend 0.94 0.87–1.02 0.120 0.99 0.88–1.13 0.914 0.88 0.79–0.98 0.026 0.95 0.86–1.06 0.404 0.264
MODEL 2
H. pylori+ 0.91 0.71–1.16 0.434 1.14 0.74–1.73 0.556 0.72 0.52–1.01 0.059 0.95 0.68–1.34 0.784 0.168
Number of proteins+
<4 1.00 1.00 1.00 1.00
4–7 1.00 0.77–1.31 0.972 1.20 0.76–1.90 0.430 0.78 0.54–1.13 0.191 1.10 0.76–1.60 0.615 0.198
7–12 0.96 0.74–1.24 0.739 1.25 0.81–1.95 0.313 0.80 0.56–1.14 0.217 0.93 0.65–1.34 0.709 0.230
≥12 0.63 0.46–0.85 0.003 0.73 0.43–1.25 0.254 0.45 0.29–0.71 0.001 0.76 0.50–1.16 0.200 0.143
Trend 0.87 0.80–0.95 0.002 0.92 0.80–1.06 0.265 0.82 0.72–0.93 0.002 0.89 0.79–1.00 0.058 0.385
MODEL 3
H. pylori+ 0.87 0.67–1.12 0.276 1.04 0.67–1.62 0.856 0.67 0.47–0.96 0.031 0.95 0.66–1.36 0.768 0.177
Number of proteins+
<4 1.00 1.00 1.00 1.00
4–7 1.01 0.76–1.34 0.972 1.16 0.72–1.89 0.540 0.77 0.52–1.15 0.204 1.14 0.76–1.69 0.526 0.218
7–12 0.90 0.68–1.18 0.435 1.14 0.71–1.81 0.591 0.73 0.50–1.07 0.104 0.91 0.62–1.34 0.629 0.271
≥12 0.57 0.41–0.80 0.001 0.63 0.36–1.11 0.110 0.39 0.24–0.64 <0.001 0.73 0.47–1.15 0.176 0.104
Trend 0.84 0.76–0.92 <0.001 0.88 0.75–1.02 0.085 0.78 0.68–0.89 <0.001 0.87 0.76–0.99 0.033 0.324
aFrom multilevel logistic regression mixed model.
bFrom multinomial logistic regression mixed model.
Province was included as a random-effect term in all models. Model 1: Adjusted by age, sex and education. Model 2: Additionally adjusted by smoking status, body mass index and
family history of colorectal cancer. Analysis based on 2,138 controls, 1,160 colorectal, 299 right colon, 394 left colon, and 450 rectal cancer cases with complete information for all the
covariates. Model 3: Additionally adjusted by total energy intake, past ethanol intake, vegetables intake and red and processed meat intake. Analysis based on 1,914 controls, 1,031
colorectal, 265 right colon, 342 left colon and 409 rectal cancer cases with complete information for all the covariates. Trend corresponds to the OR for each increasing category of
number of proteins seropositive. P-het, p-values for the heterogeneity among tumor sites. Associations with a p < 0.05 are highlighted in bold.
HP305 higher seroreactivities were associated with decreasing
CRC risk: 11% (p < 0.001) and 8% (p = 0.011) lower for each
tertile with respect to seronegativity, respectively. Results were
similar for the three tumor sites analyzed, with no statistically
significant heterogeneity.
Results from the analysis stratified by sex and age group
suggested a different effect of H. pylori infection on the risk
of CRC according to the combination of these characteristics.
Women older than 64 years showed a nearly statistically
significantly increased risk of CRC associated with H. pylori
seropositivity (OR = 1.74; 95% CI: 0.99–3.08; p-value: 0.055),
while no effect was observed for men of the same age group
(OR = 1.18; 95% CI: 0.77–1.82; p-value: 0.452) or for younger
women (OR = 0.95; 95% CI: 0.61–1.49; p-value: 0.834). On the
other hand, in men under 65 years old H. pylori seropositivity
was related to a lower CRC risk (OR = 0.61; 95% CI: 0.39–
0.97; p-value: 0.036). The effect of seropositivity for individual
proteins among infected subjects also showed differences by sex
and age (Figure 3). Inverse associations were estimated for some
proteins in men of the younger age group (<65 years old), while
for both, men and women over 64 years most of the estimated OR
were around unity, showing no effect. Interaction was statistically
significant for GroEL, HP231, HpaA, and HomB. GroEL was
associated with an increased CRC risk mainly in the age group
over 64 years, being the association statistically significant only
for women. HP231 showed a lower CRC risk in men under 65,
a nearly significantly higher risk in men older than 64, and no
effect in women. HpaA showed a lower CRC risk in men of both
age groups and no effect in women. Lastly, HomB seropositivity
was related to a lower risk of CRC only inmen older than 64, with
no effect in the other three groups.
DISCUSSION
This is one of the largest case-control studies published to date
assessing the relation between CRC and H. pylori infection.
Our results point to a lack of increased CRC risk associated
with H. pylori infection. After controlling for the main known
risk factors for CRC, neither H. pylori seropositivity, nor
seropositivity against any of the analyzed proteins showed an
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FIGURE 2 | Association of the seropositivity against each of the studied H. pylori proteins with the risk of colorectal cancer among H. pylori
seropositive participants (positive for four or more H. pylori proteins), overall and by tumor site. ORs from multinomial logistic regression mixed model
adjusted by age, sex, education, family history of colorectal cancer, and smoking status; province included as a random-effect term. Statistically significant
associations are highlighted in black. Analyses based on 2,476 controls, 1,467 colorectal, 395 right colon, 500 left colon, and 550 rectal cancer cases with complete
information for all the covariates.
increased risk of colon or rectum cancer. On the contrary,
seropositivity against some H. pylori proteins, such as HP305,
HpaA, and Cagδ was associated with a 15–21% reduced risk
of CRC among infected subjects. When mutually adjusting for
serostatus against other proteins, only Cagδ continued to show
a statistically significant inverse association with CRC. Although
this result could be due to chance, the dose-response trend
observed for seroreactivity against this protein precludes us from
categorically discarding a real association between seropositivity
to this protein and a lower risk of CRC. To our knowledge,
no clear physiopathological mechanism has been described to
explain a possible protective role of Cagδ positive H. pylori
infection in the development of CRC. Cagδ is one of the proteins
forming the cag Type IV Secretion System of H. pylori. Integrity
of this system has been implicated in several mechanisms
favoring gastric carcinogenesis, but the specific function of Cagδ
has not been fully elucidated. If our results were replicated in
other studies, in depth research on the functions of Cagδ would
be warranted.
Interestingly, no increased risk was associated with
seropositivity to CagA (cytotoxin-associated gene A). This
protein is a cytotoxin injected byH. pylori into the epithelial cells
of the host that has been implicated in gastric carcinogenesis.
Therefore, this finding further supports a lack of association
of H. pylori infection with an increased risk of CRC or, in
case of such an association to exist, the involvement of other
carcinogenic mechanisms different from those mediated by
CagA cytotoxicity.
Seropositivity against GroEL, a protein pertaining to the
group of chaperons that has been related to gastric and CRC
in some previous studies (Gao et al., 2009; Epplein et al.,
2013; Murphy et al., 2015), was associated with an increased
CRC risk in infected subjects in our sample when adjusting
by serostatus against other proteins. This result should be
interpreted cautiously, given that this is a highly conserved
protein and serological analysis may have lower specificity
due to cross-reaction with the corresponding proteins of other
species. On the other hand, this result could be considered as
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FIGURE 3 | Association of the seropositivity against each of the studied H. pylori protein with the risk of colorectal cancer among H. pylori
seropositive participants, by gender and age-group. ORs adjusted by education, age (as a continuous variable), smoking status, and family history of colorectal
cancer. Province included as a random-effect term. Statistically significant interactions are highlighted in black.
supporting of a role of infections in general in the development
of CRC.
Analyses stratified by age and sex showed some indications
for a different association of the infection with the risk of CRC.
H. pylori seropositivity was associated with a 74% higher odds
of CRC in older women (4% increased risk for each additional
seropositivity) and with a 39% lower risk in younger men (8%
decreased risk for each additional seropositivity). With respect
to the effect of seropositivity against individual proteins among
H. pylori positive subjects, the decreasing risk associated with
some of them was more evident in men and in younger age
groups. Although age differences have been described on the
relation of H. pylori infection and gastric cancer in some studies
(Eybpoosh et al., 2015), there is not a general agreement in this
point, neither a demonstration of such an effect for CRC. To the
extent of our knowledge, no clear explanation has been largely
accepted for this finding, and neither for a possible difference
between men and women. However, this is a scarcely addressed
issue and most of the published studies do not present their
results stratified by age or sex, and consequently these factors are
not generally included in sensitivity analyses of meta-analyses.
An exception is the meta-analysis by Wu et al. (2013) that
reported their results stratified by sex. A higher effect ofH. pylori
infection on the risk of CRC was estimated in women than in
men, although the number of studies included was low and the
authors concluded that there was no evidence for a different
effect by sex. Our results could be taken into account to promote
the realization of analyses stratified by these factors, in order to
ascertain whether such an effect modification exits.
Given that differences in the predominant carcinogenesis
pathways have been reported between right and left colon
cancer, we evaluated whether the consequences of H. pylori
infection differed by tumor site. Although statistical test for
heterogeneity did not reveal significant differences, the observed
inverse associations were statistically significant mainly for left
colon cancer. This was true both for H. pylori seropositivity
and for individual proteins among infected subjects. Therefore,
we are cautious before rejecting a potential differential effect by
tumor site.
In agreement with our results, two recently published nested
case-control studies using also the multiplex serology technique
to test H. pylori infection reported no statistically significant
association betweenH. pylori seropositivity and colorectal, colon,
or rectum cancer (Epplein et al., 2013; Blase et al., 2016). They
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did not find an association with CagA seropositivity either.
However, Epplein et al. reported a higher risk of CRC for
seropositivity against HcpC, HP305, VacA, HP231, and NapA,
not encountered in our sample. These associations were further
supported by a statistically significant dose-response pattern and
were more evident for colon than for rectum cancer, although
the low number of rectum cancer cases studied limits the
interpretation of observed site-dependent differences, and they
did not differentiate between right and left colon.
Regarding biological mechanisms that could be involved in
a protective effect of H. pylori infection or of the infection
with certain H. pylori strains over the development of CRC,
several issues have to be mentioned. First of all, if H. pylori has
been living with the human being for the last 50,000–70,000
years (Linz et al., 2007), one could assume that it has been
playing a role in the ecosystem formed by human gastrointestinal
tract microbiota. Therefore, in spite of the decrease of gastric
cancer incidence largely attributed to the continuous reduction
of H. pylori infection rates (secondary to the widespread use of
antibiotics and the increase of the standard of living of most
populations worldwide), the disappearance of H. pylori could
be a cause of a detrimental alteration of the gastrointestinal
microbiota (Kienesberger et al., 2016; Yap et al., 2016). The role
of dysbiosis in human pathology is an area of increasing interest
and the focus of multiple experimental and clinical research.
With respect to CRC, several mechanisms have been proposed
to explain the influence of gut microbiota on its development
(Drewes et al., 2016). These include (1) a direct carcinogenic
effect of individual bacterial species on the colonic epithelial cells,
(2) an effect of the microbiota as a whole (which could modify the
products derived from diet and metabolism, either in a beneficial
or a harmful direction), or (3) mechanisms mediated by bacterial
biofilm formation (such as favoring contact between bacteria and
epithelial cells or causing a chronic inflammatory response). The
disappearance of H. pylori infection would leave an ecological
niche that, if occupied by harmful species could increase the risk
of CRC (Butt et al., 2016; Drewes et al., 2016). Differences in the
microbiota and in dietary habits between men and women and
among age-groups in the population could therefore modulate
the effect of H. pylori infection, which would be compatible with
our finding of an effect modification associated with these factors.
Some limitations should be taken into account when
interpreting our results. The case-control design of the study
does not allow establishing or discarding causal relations. Also,
residual confounding may remain due to lack of information
about not measured potential confounding factors or to
misclassification or insufficient accuracy of measured variables.
In addition, a potential selection bias could be affecting our fully-
adjusted results due to the lack of information on variables related
to diet and BMI in a non-negligible proportion of subjects in
our sample. However, in a sensitivity analysis done over the
sample with complete data for these variables, the estimated
ORs for H pylori seropositivity and for number of proteins
seropositive did not change after including these variables into
the model (data not shown). With respect to the measurement
of the exposure, classification of infection based on serological
tests does not differentiate between current and past infection.
Besides, serological response depends not only on the exposure
to the microorganisms but also on other factors such as the
antigenicity of the different microbial proteins or the immune
status of the host. Therefore, the interpretability of our results in
terms of an effect directly attributed to the expression of proteins
byH. pylori is limited. Particularly, a reverse causation secondary
to immunosuppression potentially associated with cancer or
oncological treatments cannot be ruled out. Lastly, the high H.
pylori seroprevalence among controls in our sample, could lead
to an underestimation of the OR.
This study has also several strengths. We included a
high number of histologically confirmed incident colon and
rectum cancer cases and recruited population-based controls.
Furthermore, a reliable questionnaire was used which allowed to
collect exhaustive information so that analyses were adjusted for
many recognized CRC risk factors. In addition to the covariates
included in the models presented here, we replicated all the
analyses but adjusting also by the use of proton pump inhibitors
and of non-steroidal anti-inflammatory drugs, and the results
remained practically unaltered, which reinforces our confidence
on the outcomes. Controlling for potential confounding factors
has been determined as an important methodological tool in
order to obtain unbiased estimates of the association between
H. pylori infection and CRC (Zhang et al., 2012). In this same
line, we did a crude analysis of our data, and the OR estimate
for the association of H. pylori infection with CRC risk was 1.20,
while the adjusted estimate was 0.85, supporting the importance
of including potential confounding covariates in the statistical
models and suggesting that some associations reported from
studies done without such an adjustment could overestimate
the effect. Besides, in our study statistical models included
a random province-specific intercept term, which accounted
for unexplained heterogeneity across different regions. The
relatively high number of cases of rectum cancer included in
our sample is other strength of the study, given that rectum
cancer cases have frequently been underrepresented in other
epidemiological studies in the field. In addition, we evaluated
potential interactions by age, sex, and education. Finally, we
used an emerging technology to measure the serological response
against a wide range of H. pylori proteins, including some of the
more widely recognized virulence factors, such as CagA, VacA,
UreA, and Catalase.
To our knowledge, this is the first study that evaluates the
association between H. pylori infection and CRC in Spain. Our
results suggest that H. pylori seropositivity is not associated
with a higher risk of colon or rectum cancer in the studied
population. Antibody seroreactivity to CagA, highly associated
with non-cardia gastric cancer, did not represent an increased
risk either. On the contrary, we identified seropositivity against
three individual proteins, mainly Cagδ, as markers of a reduced
risk of CRC within this population, characterized by a high
H. pylori seroprevalence. Our results point at a possible difference
between sexes and age groups on the role of serological response
against H. pylori infection either as a risk factor for or as a
marker of CRC risk. If this finding was confirmed, differences in
outcomes among published studies could be attributed in part
to different population characteristics in terms of age and sex.
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Lastly, no statistical heterogeneity was identified in the effect of
the infection among tumor sites, although some indications of a
decreased risk for left colon cancer were observed.
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